The analyst behind the change is now bullish on Teva's future. The person behind the modification was JPMorgan Chase analyst Chris Schott, who pushed up his Teva stock recommendation one notch ...

From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO Richard Francis is paying off. Now, following the completion of the ...

JP Morgan analysts see a potential lifeline for Teva Pharmaceutical (NYSE:TEVA) after upgrading the stock to Overweight and raising the price target to $23. The move follows Teva's announcement of ...

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) reaffirmed 2027 financial targets, including 30% operating profit margin, driven by growth and transformation programs. The company said its ...

For example, during hurricanes Milton and Helene, Teva donated over 1.5 million doses of products including medications indicated in diabetes, CVD, respiratory diseases, diarrhea, epilepsy and ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has unveiled new data at the 2025 Psych Congress Elevate, highlighting significant advances in schizophrenia treatment. Real-world studies show ...

My name is Dennis Ding, biotech analyst here at Jefferies. I have the great pleasure of having Teva here with us. Welcome. Sure. Yes. So we have been on an amazing journey, and it's been a really ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced results from a study of treatment patterns among patients with tardive dyskinesia (TD ...

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva”) announced today the early tender results in connection with its previously ...

Teva outlines acceleration path into a leading biopharma company Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab ...

In terms of cash flow, Teva projects a free cash flow exceeding $2.7 billion in 2027, and over $3.5 billion by 2030. The firm also plans to reduce its payment of debt down to 2x net leverage.